Infertility in women with polycystic ovary syndrome and the role of metformin in management

References

• Azziz R, Carmina E, Dewailly D et al. Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J. Clin. Endocrinol. Metab. 91(11), 4237–4245 (2006).
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis Kandarakis, Kandarakis H, Legro R. The role of genes and environment in the etiology of PCOS. Endocrine 30(1), 19–26 (2006).
   PubMed Web of Science ®Google Scholar
• March W, Moore V, Willson K, Phillips D, Norman R, Davies M. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum. Reprod. 25(2), 544–551 (2010).
   PubMed Web of Science ®Google Scholar
• Dunaif A, Segal K, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38(9), 1165–1174 (1989).
   PubMed Web of Science ®Google Scholar
• Teede H, Hutchison S, Zoungas S. The management of insulin resistance in polycystic ovary syndrome. Trends Endocrinol. Metab. 18(7), 273–279 (2007).
   PubMed Web of Science ®Google Scholar
• Stepto NK, Cassar S, Joham AE et al. Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp. Hum. Reprod. 28(3), 777–784 (2013).
   PubMed Web of Science ®Google Scholar
• DeUgarte C, Bartolucci C, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil. Steril. 83(5), 1454–1460 (2005).
   PubMed Web of Science ®Google Scholar
• Farah-Eways L, Reyna R, Knochenhauer ES, Bartolucci AA, Azziz R. Glucose action and adrenocortical biosynthesis in women with polycystic ovary syndrome. Fertil. Steril. 81(1), 120–125 (2004).
   PubMedGoogle Scholar
• Costello M, Eden J. A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome. Fertil. Steril. 79, 1–13 (2003).
   PubMed Web of Science ®Google Scholar
• Utiger RD. Insulin and the polycystic ovary syndrome. N. Engl. J. Med. 335(9), 657–658 (1996).
   PubMedGoogle Scholar
• Azziz R, Marin C, Hoq L, Badamgarav E, Song P. Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span. J. Clin. Endocrinol. Metab. 90(8), 4650–4658 (2005).
   PubMed Web of Science ®Google Scholar
• Misso M, Costello M, Garrubba M et al. Metformin versus clomiphene citrate for infertility in non-obese women with PCOS: a systematic review and meta-analysis. Hum. Reprod. Update 19(1), 2–11 (2012).
   PubMedGoogle Scholar
• PCOS Australian Alliance. Evidence-Based Guidelines for Assessment and Management of Polycystic Ovary Syndrome. Jean Hailes Foundation for Women's Health on behalf of the PCOS Australian Alliance, Melbourne, Australia (2011).
   Google Scholar
• Teede H, Misso M, Deeks A et al. Assessment and management of polycystic ovary syndrome: summary of an evidence-based guideline. Med. J. Aust. 195(6), S65–S112 (2011).
   PubMed Web of Science ®Google Scholar
• Kafy S, Tulandi T. New advances in ovulation induction. Curr. Opin. Obstet. Gynecol. 19, 248–252 (2007).
   PubMedGoogle Scholar
• Legro R, Barnhart H, Schlaff W et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N. Engl. J. Med. 356(6), 551 (2007).
   PubMedGoogle Scholar
• Legro R, Kunselman A, Brzyski R. NICHD Reproductive Medicine Network. The Pregnancy in Polycystic Ovary Syndrome II (PPCOS II) trial: rationale and design of a double-blind randomized trial of clomiphene citrate and letrozole for the treatment of infertility in women with polycystic ovary syndrome. Contemp. Clin Trials, (33), 470–481 (2012).
   PubMedGoogle Scholar
• Moragianni V, Jones S, Ryley D. The effect of body mass index on the outcomes of first assisted reproductive technology cycles. Fertil. Steril. (98), 102–108 (2012).
   PubMed Web of Science ®Google Scholar
• Palomba S, Falbo A, Zullo F, Orio FJ. Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr. rev. 30(1), 1–50 (2009).
   PubMed Web of Science ®Google Scholar
• Elizur S, Tuland T. Drugs in infertility and fetal safety. Fertil. Steril. 89, 1595–1602 (2008).
   PubMedGoogle Scholar
• Velazquez E, Mendoza S, Hamer T, Sosa F, Glueck C. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 43(5), 647–654 (1994).
   PubMed Web of Science ®Google Scholar
• Brown J, Farquhar C, Beck J, Boothroyd C, Hughes E. Clomiphene and anti-oestrogens for ovulation induction in PCOS. Cochrane Database Syst. Rev. (4), CD002249 (2009).
   Google Scholar
• Creanga A, Bradley H, McCormick C, Witkop C. Use of metformin in polycystic ovary syndrome: a meta-analysis. Obstet. Gynecol. 111(4), 959–968 (2008).
   PubMedGoogle Scholar
• Moll E, van der Veen F, van Wely M. The role of metformin in polycystic ovary syndrome: a systematic review. Hum. Reprod. Update 13(6), 527–537 (2007).
   PubMedGoogle Scholar
• Tang T, Lord J, Norman R, Yasmin E, Balen A. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst. Rev. 2012(1), CD003053 (2012).
   Google Scholar
• Hoeger K, Davidson K, Kochman L, Cherry T, Kopin L, Guzick D. The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. J. Clin. Endocrinol. Metab. 93(11), 4299–4306 (2008).
   PubMed Web of Science ®Google Scholar
• Hoeger K, Kochman L, Wixom N, Craig K, Miller R, Guzick D. A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertil. Steril. 82(2), 421–429 (2004).
   PubMed Web of Science ®Google Scholar
• Gambineri A, Patton L, Vaccina A et al. Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. J. Clin. Endocrinol. Metab. 91(10), 3970–3980 (2006).
   PubMed Web of Science ®Google Scholar
• Karimzadeh M, Javedani M. An assessment of lifestyle modification versus medical treatment with clomiphene citrate, metformin, and clomiphene citrate-metformin in patients with polycystic ovary syndrome. Fertil. Steril. 94(1), 216–220 (2010).
   PubMed Web of Science ®Google Scholar
• Qublan H, Yannakoula E, Al-Qudah M, El-Uri F. Dietary intervention versus metformin to improve the reproductive outcome in women with polycystic ovary syndrome. A prospective comparative study. Saudi Med. J. 28(11), 1694–1699 (2007).
   PubMed Web of Science ®Google Scholar
• Misso M, Teede H, Hart R et al. Clomiphene citrate and metformin for infertility in PCOS:systematic review. Trends Endocrinol. Metab. 23(10), 533–535 (2012).
   PubMedGoogle Scholar
• Tang T, Balen AH. Use of metformin for women with polycystic ovary syndrome. Hum. Reprod. Update 19(1), 1 (2013).
   PubMedGoogle Scholar
• Johnson N, Stewart A, Falkiner J et al. PCOSMIC: a multi-centre randomized trial in women with PolyCystic Ovary Syndrome evaluating Metformin for Infertility with Clomiphene. Hum. Reprod. 25(7), 1675–1683 (2010).
   PubMed Web of Science ®Google Scholar
• Siebert T, Kruger T, Lombard C. Evaluating the equivalence of clomiphene citrate with and without metformin in ovulation induction in PCOS patients. J. Assist. Reprod. Genet. 26(4), 165–171 (2009).
   PubMedGoogle Scholar
• Kazerooni T, Ghaffarpasand F, Kazerooni Y, Kazerooni M, Setoodeh S. Short-term metformin treatment for clomiphene citrate-resistant women with polycystic ovary syndrome. Int. J. Gynaecol. Obstet. 107(1), 50–53 (2009).
   PubMed Web of Science ®Google Scholar
• Palomba S, Pasquali R, Orio F, Nestler JE. Clomiphene citrate, metformin or both as first-step approach in treating anovulatory infertility in patients with polycystic ovary syndrome (PCOS): a systematic review of head-to-head randomized controlled studies and meta-analysis. Clin. Endocrinol. (Oxf.) 70(2), 311–321 (2009).
   PubMed Web of Science ®Google Scholar
• Gilbert C, Valois M, Koren G. Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis. Fertil. Steril. 86(3), 658–663 (2006).
   PubMed Web of Science ®Google Scholar
• Ekpebegh CO, Coetzee EJ, van der Merwe L, Levitt NS. A 10-year retrospective analysis of pregnancy outcome in pregestational Type 2 diabetes: comparison of insulin and oral glucose-lowering agents. Diabet. Med. 24(3), 253–258 (2007).
   PubMedGoogle Scholar
• Glueck CJ, Phillips H, Cameron D, Sieve-Smith L, Wang P. Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. Fertil. Steril. 75(1), 46–52 (2001).
   PubMed Web of Science ®Google Scholar
• Morin-Papunen L, Rantala AS, Unkila-Kallio L et al. Metformin improves pregnancy and live-birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double-blind, placebo-controlled randomized trial. J. Clin. Endocrinol. Metab. 97(5), 1492–1500 (2012).
   PubMed Web of Science ®Google Scholar
• Palomba S, Falbo A, Orio F, Jr., Zullo F. Effect of preconceptional metformin on abortion risk in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Fertil. Steril. 92(5), 1646–1658 (2009).
   PubMed Web of Science ®Google Scholar
• Fauser BC, Tarlatzis BC, Rebar RW et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil. Steril. 97(1), 28–38 e25 (2012).
   PubMed Web of Science ®Google Scholar
• Palomba S, Falbo A, Russo T et al. Insulin Sensitivity after Metformin Suspension in Normal-Weight Women with Polycystic Ovary Syndrome. J. Clin. Endocrinol. Metab. 92(8), 3128–3135 (2007).
   PubMed Web of Science ®Google Scholar
• Wild R, Carmina E, Diamanti-Kandarakis E et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the androgen excess and polycystic ovary syndrome (AE-PCOS) society. J. Clin. Endocrinol. Metab. 95(5), 2038–2049 (2010).
   PubMed Web of Science ®Google Scholar
• Janci MM, Smith RC, Odegard PS. Polycystic ovarian syndrome: Metformin or Thiazolidinediones for cardiovascular risk reduction? Diabetes Spectr. 25(4), 229–237 (2012).
   Google Scholar